The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.
All News
Article
Article
The 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.
Article
A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.
Article
The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK).
Interested in our most popular articles? Head over to RheumNow.
https://t.co/8JLpph3or8
Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs https://t.co/yZhgVT0xLh
Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg
Top Tweet in January
Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.
https://t.co/j0BRs9snVH https://t.co/4OTmbNJ2GP
RheumNow Live: Shorter Lectures, More Discussion - Rheumatologists like us, go to meetings like this; meetings that matter; meetings that change thinking
We have a packed agenda with experts from around the world.
https://t.co/94QmsCqSdj https://t.co/DIJrI8hwDa
Study of Academic Clinicians showed that for every $1 generated though office visits (E&M coding) by 5 practicing academic rheums, $12.14 were generated through downstream revenue (mostly infusions). https://t.co/YQ1RL5JF9u
The US FDA has published a 52 page report entitled, "DRUG SAFETY PRIORITIES 2021" covering, REMS, Sentinal program, Drug safety communications (eg, Xeljanz), nitrosamine impurities (NMDA), opioids, COVID drug safety & more...https://t.co/vcMZqkdsz5
We are excited to announce that Dr. Ernest Choy will be joining us at RheumNow Live, leading a presentation on Precision Medicine in Rheumatoid Arthritis.
Join the discussion on March 19-20.
Invigorate, Instigate and Debate Rheumatology at #RNL2022
https://t.co/4uXQfRvRgc https://t.co/7KcPXadGcY
Following a mild bout of COVID-19, Dr. Kathryn Dao, shares insights on the best way to handle mild cases whether it is yourself or a friend/family member who has COVID19.
https://t.co/mevbQVNjPp
( @KDAO2011) https://t.co/CSzB9ChH3r
Article in JAMA estimates that there are 110,000 LESS deaths per year when US adults aged 40-85 years or older had a modest increase in their modest increases in moderate-to-vigorous physical activity intensity per day (ie, 10 minutes per day) https://t.co/n1ictmjnqi
2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR
ICYMI: MMWR reports >40,000 pregnant women who received COVID-19 vaccination during pregnancy- VAX not associated with preterm birth or small-for-gestational-age at birth overall compared with unvaccinated pregnant women. https://t.co/GtRMsNrFnn
ICYMI: How Preventable Is Rheumatoid Arthritis?
https://t.co/epc6BvYKzq https://t.co/2hKIuE66zT
ICYMI: NEJM clinical case -42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/zXTQYfPa1t
ICYMI: Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA
https://t.co/My5xa8vEaP https://t.co/lGL57nwJiZ
ICYMI: FDA Approves Skyrizi for Active Psoriatic Arthritis
https://t.co/0HpoZYHK2V https://t.co/pvIC6ECqjF


